Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

(2017) A. B. Sanchez Spitman et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen

(2017) Werner Schroth et al.   Frontiers in Pharmacology

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset

(2017) Per Damkier et al.   Scientific Reports

Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients

(2016) Joanne Siok Liu Lim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study

(2016) Hitoshi Zembutsu et al.   CLINICAL CANCER RESEARCH

Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, andABCB1

(2016) Jennifer L. Powers et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

(2016) Daniel L. Hertz et al.   ONCOLOGIST

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

(2015) J. A. Johnson et al.   JNCI-Journal of the National Cancer Institute

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

(2015) Stephanie L. Safgren et al.   Pharmacogenetics and Genomics

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

(2015) J. A. Johnson et al.   JNCI-Journal of the National Cancer Institute

Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis

(2014) Lan Bai et al.   Asian Pacific Journal of Cancer Prevention

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

(2014) K R Crews et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients

(2014) Philipp Y. Maximov et al.   JNCI-Journal of the National Cancer Institute

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

(2014) Olivia Pagani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

(2014) P Saladores et al.   PHARMACOGENOMICS JOURNAL

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

(2013) K. Beelen et al.   BREAST CANCER RESEARCH AND TREATMENT

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

(2013) M A Province et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

PharmGKB summary

(2013) Daniel J. Klein et al.   Pharmacogenetics and Genomics

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

(2012) M. P. Goetz et al.   CLINICAL CANCER RESEARCH

Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen

(2012) Juhyun Kim et al.   INTERNATIONAL JOURNAL OF CANCER

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

(2011) K R Crews et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

TheCYP2C19*2genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

(2011) Ron HN van Schaik et al.   PHARMACOGENOMICS

CYP2C19*2polymorphism is associated with increased survival in breast cancer patients using tamoxifen

(2010) Rikje Ruiter et al.   PHARMACOGENOMICS

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION